wherein: J 1 is hydrogen, substituted or unsubstituted alkyl, aryl, sulfonyl, acyl or substituted carbonyl; J 2 is hydrogen, aryl, sulfonyl or acyl; or J 1 and J 2 are linked to form a ring; provided that at least one of J 1 or J 2 is not hydrogen; J 3 and J 4 are each alkyl, halogen or hydrogen; X is CHC(R 13 Y'Y), CR 6 'R 6 , C=CR 6 R 6 , S, NR 6 or O; R 2 , R 4 and R 4" are each independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic or heteroaromatic; R 4 is NR 4 'R 4 ", alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen or hydrogen; R 2' , R 3 , R 10 R 11 and R 12 are each hydrogen; R 5 is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy or aryl carbonyloxy; R 6 and R 6 ' are each independently hydrogen, methylene, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino or arylalkyl; R 9 is hydrogen; R 8 is hydrogen, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino or arylalkyl; R 13 is hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino or arylalkyl; and Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino or arylalkyl, or pharmaceutically acceptable salts or esters thereof.
摘要翻译:式(II)的四环素化合物:其中:J 1是氢,取代或未取代的烷基,芳基,磺酰基,酰基或取代的羰基; J 2是氢,芳基,磺酰基或酰基; 或J 1和J 2连接形成环; 条件是J 1或J 2中的至少一个不是氢; J 3和J 4各自为烷基,卤素或氢; X是CHC(R 13 Y'Y),CR 6'R 6,C = CR 6 R 6,S,NR 6或O; R 2,R 4和R 4“各自独立地为氢,烷基,烯基,炔基,烷氧基,烷硫基,烷基亚磺酰基,烷基磺酰基,烷基氨基,芳基烷基,芳基,杂环或杂芳族; R 4为NR 4' 烯基,炔基,芳基,羟基,卤素或氢; R 2',R 3,R 10 R 11和R 12各自为氢; 烷基,链烯基,炔基,烷氧基,烷硫基,烷基亚磺酰基,烷基磺酰基,烷基氨基,芳基烷基,烷基羰基氧基或芳基羰基氧基; R 6和R 6'各自独立地为氢,亚甲基,羟基,卤素,硫醇,烷基,烯基,炔基,芳基,烷氧基,烷硫基,烷基亚磺酰基,烷基磺酰基,烷基氨基或芳基烷基; R 9是氢; R 8为氢,羟基,卤素,硫醇,烷基,烯基,炔基,芳基,烷氧基,烷硫基,烷基亚磺酰基,烷基磺酰基,烷基氨基或芳基烷基; R 13是氢,羟基,烷基,烯基,炔基,烷氧基,烷硫基,烷基亚磺酰基,烷基磺酰基,烷基氨基或芳基烷基; 其中Y'和Y各自独立地为氢,卤素,羟基,氰基,巯基,氨基,烷基,烯基,炔基,烷氧基,烷硫基,烷基亚磺酰基,烷基磺酰基,烷基氨基或芳基烷基或其药学上可接受的盐或酯。
摘要:
This invention relates to compounds having Formula (I) or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Het and R5-R13 are set in the specification. The invention also is directed to the use of compounds of Formula (I) for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.
摘要:
The present invention relates to inhibitors of 11-ß hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-ß hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
摘要:
The provides compounds for the treatment of sickle-cell disease. In particular, the invention provides 5-membered heterocyclic anti-sickling agents that are highly effective and nontoxic, and methods for their use. The compounds include analogues and derivatives of naturally occurring 5-hydroxymethyl-2-furfuraldehyde, 5-Ethyl-2-furfuraldehyde, 5-Methyl-2furfuraldehyde, and 2-furfuraldehyde, and prodrug forms of the compound.
摘要:
Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infections.
摘要:
Processes and compositions are provided for regulating COX2 gene expression in a cell. The process includes selecting a polyamide composition comprising N-methyl pyrrole (Py) and N-methyl imidazole (Im) to provide specific binding to DNA at a COX2 gene target site in a cell. The polyamide is then combined with the cell containing the COX2 gene, wherein the polyamide binds to the COX2 gene promoter target site and regulates transcription of the COX2 gene.
摘要:
The invention provides a new methionine aminopeptidase inhibitors with the following formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and X have the meanings given in the description. Pharmacological experiment shows that they display good inhibition activity for methionine aminopeptidase.